[Incidence of headache after continuous spinal anesthesia: a prospective study].

Ann Fr Anesth Reanim

Département d'Anesthésiologie-Réanimation chirurgicale, Hôpital Beaujon, Clichy, France.

Published: February 1990

Download full-text PDF

Source

Publication Analysis

Top Keywords

[incidence headache
4
headache continuous
4
continuous spinal
4
spinal anesthesia
4
anesthesia prospective
4
prospective study]
4
[incidence
1
continuous
1
spinal
1
anesthesia
1

Similar Publications

Peripartum cardiomyopathy (PPCM) and takotsubo cardiomyopathy (TCM) are cardiac conditions that can occur in the peripartum period. They have distinct characteristics and incidence rates; although rare, both contribute to the second leading cause of all-cause maternal mortality in the state of Missouri. PPCM can lead to heart failure, and TCM can cause acute arrhythmias leading to sudden cardiac death in otherwise healthy individuals.

View Article and Find Full Text PDF

Background: Japanese encephalitis (JE) is a zoonotic parasitic disease caused by the Japanese encephalitis virus (JEV), and may cause fever, nausea, headache, or meningitis. It is currently unclear whether the epidemiological characteristics of the JEV have been affected by the extreme climatic conditions that have been observed in recent years.

Objective: This study aimed to examine the epidemiological characteristics, trends, and potential risk factors of JE in Taiwan from 2008 to 2020.

View Article and Find Full Text PDF

Background: Postoperative headache is a medical condition that has a strong association with future recurrence and chronic headache, higher morbidity and mortality, extended hospital stays, poor quality of life and high financial burden. Despite, having these consequences, there are limited studies in the study area.

Objective: This study aimed to assess the incidence and associated factors of postoperative headache among adult elective surgical patients at the University of Gondar Comprehensive Specialized Hospital Northwest Ethiopia, April 9 to 20 June 2022.

View Article and Find Full Text PDF

The United States Food and Drug Administration approved the xanomeline-trospium combination in September 2024 for treating schizophrenia, based in part on three double-blind, randomized placebo-controlled trials in adults with schizophrenia experiencing acute psychosis. This random-effects model pairwise meta-analysis of those three trials found that xanomeline-trospium was comparable to placebo in terms of all-cause discontinuation, discontinuation rate due to adverse events, Simpson-Angus Scale score change, Barnes Akathisia Rating Scale score change, body weight change, body mass index change, blood pressure change, serum total cholesterol change, blood glucose change, QTc interval changes, and the incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation, tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and decreased appetite. However, xanomeline-trospium was associated with a higher incidence of at least one adverse event, dry mouth, hypertension, nausea, vomiting, dyspepsia, and constipation, and increased serum triglyceride compared with placebo.

View Article and Find Full Text PDF

The scope of this study was to assess the ototoxic effects and general health of farmers exposed to pesticides in the Pontal do Paranapanema region, SP, Brazil. Participants of both sexes aged 18-40, 40-60 and >60 years were allocated into two groups: Non-Exposed Group (NEG) and Occupationally Exposed Group (OEG). A questionnaire of exposure and health, meatoscopy, pure tone audiometry, logoaudiometry and immittanciometry were assessed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!